364. Scarmeas N., Stern Y., Tang M. X. et al. Mediterranean diet, lifestyle factors, and risk for Alzheimers disease // Ann Neurol. – 2006. – V. 59. – № 11. – P. 912–921.
365. Scharre D. W., Shiovitz T., Zhu Y., Amatniek J. One-week dose titration of extended release galantamine in patients with Alzheimers disease // Alzheimers dementia. – 2008. – V. 4. – № 1 (Suppl 1). – P. 30–37.
366. Scherzer C. R., Eklund A. C., Morse L. J. et al. Molecular markers of early Parkinson’s disease based on gene expression in blood // Proc Natl Acad Sci USA. – 2007. – V. 104. – № 3. – P. 955–960.
367. Sivenius J., Nissinen J., Jolkkonen J. Long-term functional consequences of transient occlusion of the middle cerebral artery in rats: a 1-year follow-up of the development of epileptogenesis and memory impairment in relation to sensorimotor deficits // Epilepsy Res. – 2003. – Vol. 54. – № 1. – P. 1–10.
368. Skorometz A. A., Ulitzky L. A. Aspectos neurologicos del hiperinsulinismo // Rev neurol (Barcelona). – 1980. – VIII, 37. – P. 173–181.
369. Steinbrook R. HIV in India // N Engl J Med. – 2008. – V. 358. – № 2. – P. 107–110.
370. Steingart R. A., Abu-Roumi M., Newman M. E. et al. Neurobehavioral damage to cholinergic systems caused by prenatal exposure to heroin or phenobarbital // Brain Res Dev Brain Res. – 2000. – V. 122. – № 1. – P. 125–133.
371. Stepens A., Logina I., Liguts V. et al. A parkinsonian syndrome in methcathinone users and the role of manganese // N Engl J Med. – 2008. – V. 358. – № 10. – P. 1009–1017.
372. Stepkina D. A., Zakharov V. V., Yakhno N. N. Mild cognitive impairment in Parkinson’s disease // Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 116.
373. Stern R. A., Robinson B., Thorner R. et al. A survey study of neuropsychiatric complaints in patients with Graves disease // J. Neuropsychiat and Clin Neurosci. – 1996. – V. 8. – № 2. – P. 181–185.
374. Strong M. J., Grace G. M., Orange J. B. et al. A Prospective study of cognitive impairment in ALS // Neurology. – 1999. – V. 53. – № 9. – P. 1665–1670.
375. Swanson J. A., Wigal S., Wigal T. et al. A comparison of one-daily extended-release methylphenidote formulations in children with at-tention-deficit HD in the laboratory school // Pediatrics. – 2004. – V. 113. – № 1. – P. 206–216.
376. Thal L. J., Kantarci K., Reiman E. M. The Role of Biomarkers in Clinical Trials for Alzheimer Disease // Alzheimer Dis Assoc Disord. – 2006. – V. 20. – № 1. – P. 6–15.
377. Thomas A. J., Kalaria R. N., O’ Brien. Depression and vascular disease // J. Affect disord. – 2004. – V. 79. – № 1. – P. 81–95.
378. Tippett L. J., Waldvogel H. J., Thomas S.J. et al. Striosomes and mood dysfunction in Huntingtons disease // Brain. – 2007. – V. 130. – Part 1. – P. 206–221.
379. Trehub S. E. Musical predispositions in infancy // Ann. NY Acad. Sci. – 2001. – V. 930. – № 6. – P. 1–10.
380. Tucker D. M., Roeltgen D. P., Wann P., Wertheimer P. Memory dysfunction in myasthenia gravis // Neurology. – 1988. – V. 38. – № 8. – P. 1173–1177.
381. Tuomilehto J., Hu G., Antikainen R., Jousilahti P. Serum cholesterol and the risk of Parkinson’s disease // Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 106.
382. Turner E. N., Matthews A. M., Linardatos E. et al. Selective publication of antidepressant trials and its influence on apparent efficacy // N. Engl. J. Med. – 2008. – V. 358. – № 3. – P. 252–260.
383. Van Es M., Vught P. W., Blauw H. M. ITPR2 as susceptibility gene in sporadic ALS // Lancet Neurology. – 2007. – V. 6. – № 10. – P. 869–877.
384. Vellas B., Gillette-Guyonnet S., Andrieu S. Memory health clinics – a first step to prevention // Alzheimers dementia. – 2008. – V. 4. – № 1 (Suppl 1). – P. 144–149.
385. Vernino S., Auger R. G., Emslie-Slie A. M. Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability // Neurology. – 1999. – V. 53. – № 6. – P. 1233–1239.
386. Vernino S., Geschwind M., Boeve B. Autoimmune encephalopathies // Neurologist. – 2007. – V. 13. – № 3. – P. 140–147.
387. Wade D. T. Measurement in neurological rehabilitation / D. T.Wade, Oxford: Oxford University Press, 1992. – 374 p.
388. Wadley V. G., Haley W. E. Diagnostic attributions versus labeling // J of Gerontology: Psychological Sciences. – 2001. – V. 56. – P. 244–252.
389. Wattmo C., Wallin A. K., Minthon Activities of daily living – outcome during two years in galantamine treated Alzheimer patients //Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 32.
390. Whitehouse P. J., Price D. L., Stuble R. G. et al. Alzheimers disease and senile dementia // Science. – 1982. – V. 215. – P. 1237–1239.
391. Wilhelm H., Roschmann R. Neuropsychologische Gutachten ein leitfaden fur Psychologen Arzte, Yuristen und Studierende // Verlag W. Kohlhammer. – 2007. – 186 p.
392. Wolf H., Hensel A., Arendt T. et al. Serum lipids and hippocampal volume //Ann Neurol. – 2004. – V. 56. – № 4. – P. 745–748.
393. Xianlin Han. Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer’s disease: a tale of shotgun lipidomics // J. Neurochem. – 2007. – V. 103 (Suppl 1). – P. 171–179.
394. Yaffe K., Kanaya A., Lindquist K. et al. The metabolic syndrom, inflammation, and risk of cognitive decline // JAMA. – 2004. – V. 5292. – № 12. – P. 2237–2242; //Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 116–117.
395. Zanetti M., Bergamaschiri L., Morichetti C. et al. The clock drawing test //Neurodegenerative Dis. – 2007. – V. 4 (Suppl 1). – P. 290.
Приложения
Приложение 1. Краткая шкала оценки психического статуса (КШОПС)
Приложение 2. Клиническая рейтинговая шкала деменции
Ноль (0) баллов – нет нарушений; 0,5 баллов – «сомнительная» деменция.
Память: постоянная незначительная забывчивость, неполное припоминание происшедших событий.
Ориентировка: ориентирован, но могут быть неточности в назывании даты.
Мышление: незначительные трудности при решении задач, анализе сходств и различий.
Взаимодействие в обществе: незначительные трудности.
Поведение дома и увлечения: незначительные трудности.
